Skip to main
ANIP
ANIP logo

ANI Pharma (ANIP) Stock Forecast & Price Target

ANI Pharma (ANIP) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

ANI Pharmaceuticals Inc. has strategically expanded its Cortrophin sales force, a move that has proven to be a significant driver of revenue success for this specific product. The company's weekly TRx tracker indicates a robust performance that surpasses previous expectations for Cortrophin, leading to heightened revenue estimates and potential multiple expansion. This proactive, data-driven strategy not only enhances the company's financial flexibility for further investments but also improves its ability to address payer-related inquiries, ultimately supporting the overall growth and profitability outlook for ANI Pharmaceuticals.

Bears say

ANI Pharmaceuticals Inc. faces a negative outlook primarily due to a significant debt burden exceeding $600 million, which may constrain its financial flexibility and operational capabilities. The company is also vulnerable to various risks, including pricing pressures across its portfolio, reimbursement challenges, and competitive threats in the pharmaceutical market. Additionally, past reputational issues related to its ACTH category products further complicate its commercial execution and could impede growth.

ANI Pharma (ANIP) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ANI Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ANI Pharma (ANIP) Forecast

Analysts have given ANI Pharma (ANIP) a Buy based on their latest research and market trends.

According to 6 analysts, ANI Pharma (ANIP) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $100, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $100, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ANI Pharma (ANIP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.